ArticleACS applied nano materials2025
Point-of-Care Tests via Pollen-Based Nanoplasmonic Chips Combined with a Synthetic Receptor for FKBP12 Biomarker Detection at a Single-Molecule Level.
Article in ACS applied nano materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The selective and rapid detection of FKBP12 is crucial due to its involvement in immunosuppression, neurodegenerative and oncological diseases, and some fundamental cellular processes. A low-cost point-of-care test (POCT) based on a simple setup, combined with plasmonic sensor chips for ultrasensitive detection of FKBP12, is developed. The sensing principle exploits pollen-based natural nanostructures covered by gold nanofilms and functionalized with synthetic GPS-SH1 receptors. The experimental results demonstrated ultrahigh performance due to the hybrid plasmonic phenomena, with a detection limit of 0.17 aM for FKBP12. This label-free optical-chemical sensor is based on portable and simple equipment, operates in 10 min, requires a small volume of the sample, and only requires a dilution step to perform the measurement on real samples. The high selectivity of the developed sensor chip for FKBP12 is demonstrated, and its applicability in complex matrices such as serum and plasma is validated. Furthermore, two surface functionalization strategies with different receptor-to-spacer ratios, 1:6 and 1:3, are investigated, identifying the optimal ratio to achieve better binding sensitivity. This work highlights the potential of plasmonic nanostructured pollen-based chips functionalized with GPS-SH1 receptors for the detection of FKBP12 at the single-molecule level, paving the way for advances in diagnostics and therapeutic monitoring via low-cost POCT with cheaper and disposable chips.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.